This site is for healthcare professionals.

The importance of continuing a multidisciplinary approach

Multimodal treatments, which require multidisciplinary collaboration, have been shown to improve OS in patients with MIBC1

Collaboration between oncologists, urologists, radiation oncologists, and other stakeholders is recommended by the ESMO Clinical Practice Guidelines for the optimal management of MIBC.2 However, multidisciplinary collaborations between oncologists and urologists are estimated to occur in only ~17%–39% of MIBC patient cases globally.3,4

Roles throughout the MIBC treatment journey5

Treatment Journey
Treatment Journey

*Physician assistants, nurse practitioners, advanced practice pharmacists, or other advanced practice providers.

Continued collaboration between healthcare teams across all stages is essential for providing optimal care and improving outcomes for patients with MIBC2,6

This multidisciplinary approach is key to maximising surgical outcomes and increasing patients’ chances for survival.

Hear from a world-renowned urologist about the importance of collaboration between specialties and the consequences when it does not occur as it ideally should.

Despite its importance, multidisciplinary collaboration in MIBC care can be enhanced to improve patient outcomes2

aggressive-disease

What makes MIBC an aggressive disease?

current-treatment-options-and-limitations

What are the current treatment options and considerations for MIBC?

collaborative-approach-essential

Why is a collaborative approach essential in the treatment of MIBC?

APP – advance practice provider; ESMO – European Society for Medical Oncology; MIBC – muscle-invasive bladder cancer.

References: 1. Kim KH, Lee HW, Ha HK, Seo HK. Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies. Investig Clin Urol 2023;64(3):202-218. 2. Powles T, Bellmunt J, Comperat E, at al; ESMO Guidelines Committee. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33(3):244-58 3. Jerlström T, Chen R, Liedberg F, at al. No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study. World J Urol 2020;38(2):381-388. 4. Liu W, Tian J, Zhang S, at al. The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis. Minerva Urol Nephrol 2021;73(2):144-153. 5. Astellas. Urothelial Cancer Patient Journey. Data on File. 6. Park JC, Citrin DE, Agarwal PK, Apolo AB. Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer 2014;38(3):80-108.